Reference for PROTEOLIX. Search for PROTEOLIX

AI searches containing PROTEOLIX

PROTEOLIX

Proteolix

Defunct American pharmaceutical company owned by Onyx Pharmaceuticals

Proteolix, Inc., was a private biotechnology company with headquarters in South San Francisco, California. Proteolix was founded in 2003 based on technology

Proteolix

Raymond J. Deshaies

American biochemist and cell biologist

Medical Institute. He is also the co-founder of the biotechnology companies Proteolix and Cleave Biosciences. His research focuses on mechanisms and regulation

Raymond J. Deshaies

Raymond_J._Deshaies

Carfilzomib

Chemical compound

Proteolix, Inc. Scientists at Proteolix invented a new, distinct compound that had potential use as a drug in humans, known as carfilzomib. Proteolix

Carfilzomib

Onyx Pharmaceuticals

American pharmaceutical company

9, 1996. In 2009, the company acquired private biotechnology company Proteolix for US$276 million in cash plus additional milestone payments. In January

Onyx Pharmaceuticals

Onyx_Pharmaceuticals

List of pharmaceutical companies

(1993–2003; acquired by Chiron) Profound (1999–2008; acquired by Maxygen) Proteolix (2003–2009; acquired by Onyx) Purdue (1892–2019; bankrupt) Ranbaxy Laboratories

List of pharmaceutical companies

List_of_pharmaceutical_companies

Amgen

American multinational biopharmaceutical company

(Acq 2012) deCODE genetics (Acq 2012) Onyx Pharmaceuticals (Acq 2013) Proteolix(Acq 2009) NextCODE genetics (Spun off 2013) Dezima Pharma (Acq 2015) Catherex

Amgen

U.S. Venture Partners

American venture capital investment firm

Ross Stores, Ask Jeeves, Adify, PetSmart, Check Point, Mellanox, Vontu, Proteolix, Dotomi, Imperva, Guidewire Software, Yammer, Trusteer, Nanostim and Trunk

U.S. Venture Partners

U.S._Venture_Partners

Craig M. Crews

American scientist

inhibitor, YU101. In 2003, Crews co-founded the biotechnology company Proteolix to develop YU101, which ultimately served as the parent compound of multiple

Craig M. Crews

Craig_M._Crews

Multiple Myeloma Research Consortium

trials with industry partners – including Novartis, Celgene, Merck, and Proteolix. MMRC clinical trials are also designed to include correlative studies

Multiple Myeloma Research Consortium

Multiple_Myeloma_Research_Consortium

Oprozomib

Chemical compound

an orally active second-generation proteasome inhibitor developed by Proteolix, which was acquired by Onyx Pharmaceuticals, an Amgen subsidiary, in 2009

Oprozomib